Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00097266 · ClinicalTrials.gov registry record · Phase 3
Study of Aripiprazole in Patients With Acute Bipolar Mania
A Phase 3 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 3
- Development phase
- 615
- Enrollment target
NCT00097266 is a Phase 3 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 615 participants.
The verdict
NCT00097266, a Phase 3 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 615 participants
- Enrollment target
Study Summary
The purpose of this research study is to confirm the safety and effectiveness of aripiprazole therapy over 12 weeks in subjects with bipolar disorder experiencing symptoms of mania.
Interventions
- DRUG Placebo
- DRUG Haloperidol
- DRUG Aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 615 participants |
| Start Date | 2004-12 |
| Est. Completion | 2007-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00097266
The ClinicalTrials.gov registry entry for NCT00097266 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 615 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00097266 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00097266 about?
NCT00097266 is a clinical study titled "Study of Aripiprazole in Patients With Acute Bipolar Mania". The purpose of this research study is to confirm the safety and effectiveness of aripiprazole therapy over 12 weeks in subjects with bipolar disorder experiencing symptoms of mania.
What is the current status of trial NCT00097266?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 615 participants. The study started on 2004-12. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00097266?
The interventions under investigation include: Placebo (DRUG), Haloperidol (DRUG), Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00097266?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.